Role of blood tumor markers in predicting metastasis and local recurrence after curative resection of colon cancer.

AIM To investigate the prognostic value of carcinoembryonic antigen (CEA), CA199, CA724 and CA242 in peripheral blood and local draining venous blood in colon cancer patients after curative resection. METHODS 92 colon cancer patients who received curative resection were retrospectively analyzed. The CEA, CA199, CA724 and CA242 were detected in peripheral blood and local draining venous blood. RESULTS Metastasis or local recurrence was found in 29 (29/92, 31.5%) patients during follow-up period. 92 patients were divided into two groups: metastasis/local recurrence group (n = 29) and non-metastasis/local recurrence group (n = 63). Peripheral venous CEA, CA199, CA724 and CA242 (p-CEA, p-CA199, p-CA724 and p-CA242) were comparable between two groups (P > 0.05). The median draining venous CEA (d-CEA) in metastases/local recurrence group (23.7 ± 6.9 ng/ml) was significantly higher than that in non-metastases/local recurrence group (18.1 ± 6.3 ng/ml; P < 0.05), but marked differences were not observed in draining venous CA199, CA724 and CA242 (d-CA199, d-CA724 and d-CA242) between two groups (P > 0.05). The optimal cut-off value of d-CEA was 2.76 ng/ml, with the sensitivity and specificity of 90% and 40% in the prediction of metastasis or local recurrence, respectively. d-CEA correlated with tumor differentiation, T stage, TNM stage, metastasis and local recurrence. Subgroup analysis showed that, of 41 patients with stage II colon cancer, the optimal cut-off value of d-CEA was 8.78 ng/mL, and the sensitivity and specificity were 87.5% and 69.7% in the prediction of metastasis or local recurrence, respectively. CONCLUSION d-CEA may be a prognostic factor for stage II colon cancer patients.

[1]  Long-bin Xiao,et al.  Tumour budding is a reproducible index for risk stratification of patients with Stage II colon cancer , 2014, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[2]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[3]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[4]  V. Heinemann,et al.  Tumor markers CEA and CA 19-9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy , 2014, Tumor Biology.

[5]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Zacharakis,et al.  Prognostic significance of CEA levels and detection of CEA mRNA in draining venous blood in patients with colorectal cancer , 2006, Journal of surgical oncology.

[7]  Yan Li,et al.  Preoperative serum carbohydrate antigen 242 is a useful predictive and prognostic marker in colorectal cancer. , 2011, Hepato-gastroenterology.

[8]  Carolyn Compton,et al.  American Joint Committee on Cancer prognostic factors consensus conference , 2000, Cancer.

[9]  Jaw-Yuan Wang,et al.  Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment , 2009, BMC Cancer.

[10]  Hartmut Link,et al.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[11]  M. Thompson,et al.  Evidence of the effect of ‘specialization’ on the management, surgical outcome and survival from colorectal cancer in Wessex , 2003, The British journal of surgery.

[12]  J. Waisberg,et al.  Determination of carcinoembryonic antigen levels in peripheral and draining venous blood in patients with colorectal carcinoma. , 2004, Arquivos de gastroenterologia.

[13]  K. Miyazaki,et al.  Clinical Significance of CEA and CA19-9 in Postoperative Follow-up of Colorectal Cancer , 2010, Annals of Surgical Oncology.

[14]  E. Mitchell,et al.  Carcinoembryonic Antigen in the Staging and Follow-up of Patients with Colorectal Cancer , 2005, Cancer investigation.

[15]  Jian Lu,et al.  Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. , 2013, The Lancet. Oncology.

[16]  H. Deguchi,et al.  Colorectal cancer patients with high risk of hematogenous metastasis: Correlation with CEA levels in peripheral and draining venous blood during the period of operation , 1991, Journal of surgical oncology.

[17]  Mingxia Yu,et al.  Predictive value of serum CEA, CA19-9 and CA125 in diagnosis of colorectal liver metastasis in Chinese population. , 2013, Hepato-gastroenterology.

[18]  T. Rockall,et al.  Carcinoembryonic antigen: its value in the follow-up of patients with colorectal cancer , 1999, International Journal of Colorectal Disease.

[19]  O. Topolcan,et al.  The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence. , 2000, Anticancer research.

[20]  V. Bardou,et al.  Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer. , 2009, Surgical oncology.

[21]  M. Brouwers,et al.  Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  H. Ahn,et al.  Carcinoembryonic antigen level of draining venous blood as a predictor of recurrence in colorectal cancer patient , 2011, Journal of the Korean Surgical Society.

[23]  G. Choi,et al.  Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer. , 2009, Anticancer research.

[24]  S. Cha,et al.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Kirkpatrick,et al.  VEGF-B expression in colorectal carcinomas and its relevance for tumor progression. , 2013, Histology and histopathology.

[26]  F. Fujita,et al.  The serum level of carcinoembryonic antigen in drainage venous blood is not a sensitive predictor of metachronous hepatic metastasis for patients with colorectal cancer , 2010, Surgery Today.

[27]  O. Topolcan,et al.  Tumor markers in staging and prognosis of colorectal carcinoma. , 2008, Neoplasma.

[28]  T. Morimoto,et al.  Does Serum CA19-9 Play a Practical Role in the Management of Patients With Colorectal Cancer? , 2004, Diseases of the colon and rectum.

[29]  D. Matos,et al.  Peripheral and mesenteric serum levels of CEA and cytokeratins, staging and histopathological variables in colorectal adenocarcinoma. , 2008, World journal of gastroenterology.

[30]  H. Deguchi,et al.  Comparison of carcinoembryonic antigen levels between portal and peripheral blood in patients with colorectal cancer correlation with histopathologic variables , 1987, Cancer.

[31]  V. Kakani,et al.  Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. , 2004, Clinical colorectal cancer.

[32]  W. Hohenberger,et al.  Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  P. Oettgen,et al.  Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. , 2005, The Journal of clinical investigation.